[PDF][PDF] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
P Kirchhof, S Benussi, D Kotecha… - Polish Heart …, 2016 - journals.viamedica.pl
Komisję ESC ds. Wytycznych Postępowania nadzoruje i koordynuje przygotowywanie
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …
[HTML][HTML] Estándares SEA 2019 para el control global del riesgo cardiovascular
Resumen La Sociedad Española de Arteriosclerosis tiene entre sus objetivos contribuir al
mayor y mejor conocimiento de la enfermedad vascular, su prevención y su tratamiento. Las …
mayor y mejor conocimiento de la enfermedad vascular, su prevención y su tratamiento. Las …
[PDF][PDF] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
F Casselman, A Coca, R De Caterina… - European heart …, 2016 - academia.edu
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …
is recommended in the guidelines, thus completing the loop between clinical research …
Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials
Introduction Supraventricular tachycardias (SVT) are a diverse group of commonly
encountered arrhythmias arising at or above the atrioventricular (AV) node. Conventional …
encountered arrhythmias arising at or above the atrioventricular (AV) node. Conventional …
[PDF][PDF] Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS
S Benussi, D Kotecha, A Ahlsson… - Rev Esp …, 2017 - sedeelectronica.comcordoba.com
Se recomienda a los profesionales de la salud que tengan en consideración la presente
guía de la ESC/EACTS en la toma de decisiones clínicas en su ejercicio diario, así como en …
guía de la ESC/EACTS en la toma de decisiones clínicas en su ejercicio diario, así como en …
Plasma omega‐3 fatty acids and the risk of cardiovascular events in patients after an acute coronary syndrome in MERLIN‐TIMI 36
TA Zelniker, DA Morrow, BM Scirica… - Journal of the …, 2021 - Am Heart Assoc
Background Plasma omega‐3 polyunsaturated fatty acids (ω3‐PUFAs) have been shown to
be inversely correlated with the risk of cardiovascular death in primary prevention. The risk …
be inversely correlated with the risk of cardiovascular death in primary prevention. The risk …
[HTML][HTML] Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives
Atrial fibrillation (AF) remains the most frequent sustained cardiac arrhythmia worldwide and
its incidence increases with ageing, cardiovascular risk factors and comorbidities …
its incidence increases with ageing, cardiovascular risk factors and comorbidities …
Ranolazine: An old drug with emerging potential; lessons from pre-clinical and clinical investigations for possible repositioning
Ischemic heart disease is a significant public health problem with high mortality and
morbidity. Extensive scientific investigations from basic sciences to clinics revealed …
morbidity. Extensive scientific investigations from basic sciences to clinics revealed …
Antiarrhythmic properties of ranolazine: a review of the current evidence
Ranolazine was developed as an antianginal agent and was approved by the Food and
Drug Administration in 2006 for use in chronic stable angina pectoris. Experimental and …
Drug Administration in 2006 for use in chronic stable angina pectoris. Experimental and …
Ranolazine for rhythm control in atrial fibrillation: a systematic review and meta-analysis
F Guerra, A Romandini, A Barbarossa… - International Journal of …, 2017 - Elsevier
Background/objectives Available pharmacological options for rhythm control strategy in
atrial fibrillation (AF) are limited by sub-optimal efficacy and potentially serious adverse …
atrial fibrillation (AF) are limited by sub-optimal efficacy and potentially serious adverse …